Induction Therapy for Lupus Nephritis: the Highlights
Induction Therapy for Lupus Nephritis: the Highlights
复制标题
DOI：
10.1007/s11926-018-0766-9
复制
发表时间：
2018-10-01
影响因子：
5
通讯作者：
Rovin, Brad H.
中科院分区：
文献类型：
--
作者：
Ayoub, Isabelle;Nelson, Jessica;Rovin, Brad H.
狼疮性肾炎是系统性红斑狼疮的常见并发症，在儿童中更为常见和严重。这是一种以T细胞、B细胞和补体激活以及免疫复合物形成和沉积为特征的免疫系统疾病。类固醇和环磷酰胺的引入将狼疮性肾炎从致命性转变为可治疗的疾病。然而，目前用于治疗的标准疗法具有显著的毒性，慢性肾脏疾病仍然是一种过于频繁的结果。为了解决这些问题，我们将审查当前和新兴的诱导疗法在LN。最近的调查结果几个临床试验已经进行测试更有效和更安全的药物，往往针对机械疾病pathways.Summary目前，很难确定一个诱导方案，是更有效和更少的毒性比标准的护理;不过，我们相信，继续致力于药物开发，将为诊所带来突破性的药物。
Purpose of Review Lupus nephritis is a frequent complication of systemic lupus erythematosus and is more common and severe in children. This is a disease of the immune system characterized by T cell, B cell, and complement activation, as well as immune complex formation and deposition. The introduction of steroids and later cyclophosphamide transformed lupus nephritis from a fatal to a treatable condition. However, the standard therapies currently used for treatment carry significant toxicity and chronic kidney disease still remains a far too frequent outcome. To address these issues, we will review current and emerging induction therapies in LN.Recent Findings Several clinical trials have been undertaken to test more effective and safer drugs, often targeting mechanistic disease pathways.Summary At present, it is difficult to identify an induction regimen that is more effective and less toxic than the standard of care; however, we believe continuing efforts in drug development will bring breakthrough agents to clinics.